US Patent Issued to HAEMALOGIX on Oct. 7 for "Anti-lambda myeloma antigen (LMA) binding proteins to treat LMA-expressing cancer and autoimmune disorders" (Australian Inventor)

ALEXANDRIA, Va., Oct. 8 -- United States Patent no. 12,435,158, issued on Oct. 7, was assigned to HAEMALOGIX LTD (Sydney).

"Anti-lambda myeloma antigen (LMA) binding proteins to treat LMA-expressing cancer and autoimmune disorders" was invented by Rosanne Dunn (Sydney).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to anti-LMA binding proteins. Such binding proteins may be useful for treating disorders associated with aberrant proliferation of plasma cells and/or their precursors."

The patent was filed on Aug. 12, 2022, under Application No. 17/819,483.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=...